BIOSYENT INC (RX.CA) Stock Analyst Ratings
Canada - TSX Venture Exchange - TSX-V:RX - CA0906901081 - Common Stock
12.73 CAD
-0.16 (-1.24%)
ChartMill assigns a Buy % Consensus number of 83% to RX.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.77. This target is 8.17% above the current price.
RX.CA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about RX.CA.
In the previous month the buy percentage consensus was at a similar level.
RX.CA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-03-10 | Raymond James Capital | Upgrade | Market Perform |
| 2021-11-19 | RaymondJamesFinancial | Initiate | Market Perform |
| 2021-08-26 | Raymond James Financial | Initiate | Market Perform |
| 2021-05-28 | Raymond James Financial | Upgrade | Market Perform |
| 2021-03-18 | Raymond James Financial | Initiate | Market Perform |
BIOSYENT INC / RX.CA FAQ
What is the price target for RX stock?
7 analysts have analysed RX.CA and the average price target is 13.77 CAD. This implies a price increase of 8.17% is expected in the next year compared to the current price of 12.73.
Can you provide the consensus rating for BIOSYENT INC stock?
The consensus rating for BIOSYENT INC (RX.CA) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover BIOSYENT INC (RX.CA) stock?
The number of analysts covering BIOSYENT INC (RX.CA) is 7.